Cargando…

Analysis of integrated clinical trial protocols in early phases of medicinal product development

PURPOSE: While in the past, most clinical trial applications (CTAs) following non-integrated (standard) protocols were used to investigate one primary objective concerning a (new) drug, nowadays, the use of integrated protocols investigating multiple objectives within the same CTA becomes more and m...

Descripción completa

Detalles Bibliográficos
Autores principales: Fruhner, Kevin, Hartmann, Gunther, Sudhop, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684304/
https://www.ncbi.nlm.nih.gov/pubmed/28921395
http://dx.doi.org/10.1007/s00228-017-2335-y
_version_ 1783278448538550272
author Fruhner, Kevin
Hartmann, Gunther
Sudhop, Thomas
author_facet Fruhner, Kevin
Hartmann, Gunther
Sudhop, Thomas
author_sort Fruhner, Kevin
collection PubMed
description PURPOSE: While in the past, most clinical trial applications (CTAs) following non-integrated (standard) protocols were used to investigate one primary objective concerning a (new) drug, nowadays, the use of integrated protocols investigating multiple objectives within the same CTA becomes more and more popular. The aims of the present study were to investigate the usage and the impact of integrated protocols on regulatory activities and to find the motivation for their increasing use. METHODS: Two thousand nine hundred sixty-nine phase I and I/II CTAs submitted to the German Federal Institute for Drugs and Medical Devices (BfArM) during the time period from August 1, 2004, until August 31, 2014, were analysed with regard to protocol and sponsor status, duration until initial authorisation and the number of substantial amendments and their respective approval times. Additionally, applicants who submitted integrated protocols to BfArM were interviewed with respect to their opinion on integrated protocols in an online survey. RESULTS: The percentage of integrated protocols has constantly increased by approximately 10% within the last 10 years from 17.9% in 2004 to 28.2% in 2014. It could be shown that authorisation procedures with single integrated protocols take significantly longer until initial authorisation (58 vs. 53 days) requires more substantial amendments (1.9 vs. 1.2 amendments per CTA) and the approval of the entirety of amendments takes longer to process as compared to standard protocols (22 vs. 14 days). Nevertheless, applicants prefer the use of integrated protocols due to higher time and cost economy for the entire phase I development process. CONCLUSION: Although clinical trials (CTs) following integrated protocols are partly more time-consuming and costly, still, time and/or money may be saved during drug development due to the fact that overall, fewer CTs are needed than with standard protocols. Hence, the main reason for the increasing use of integrated protocols is improved time and cost efficiencies when conducting CTs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00228-017-2335-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5684304
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-56843042017-11-27 Analysis of integrated clinical trial protocols in early phases of medicinal product development Fruhner, Kevin Hartmann, Gunther Sudhop, Thomas Eur J Clin Pharmacol Clinical Trial PURPOSE: While in the past, most clinical trial applications (CTAs) following non-integrated (standard) protocols were used to investigate one primary objective concerning a (new) drug, nowadays, the use of integrated protocols investigating multiple objectives within the same CTA becomes more and more popular. The aims of the present study were to investigate the usage and the impact of integrated protocols on regulatory activities and to find the motivation for their increasing use. METHODS: Two thousand nine hundred sixty-nine phase I and I/II CTAs submitted to the German Federal Institute for Drugs and Medical Devices (BfArM) during the time period from August 1, 2004, until August 31, 2014, were analysed with regard to protocol and sponsor status, duration until initial authorisation and the number of substantial amendments and their respective approval times. Additionally, applicants who submitted integrated protocols to BfArM were interviewed with respect to their opinion on integrated protocols in an online survey. RESULTS: The percentage of integrated protocols has constantly increased by approximately 10% within the last 10 years from 17.9% in 2004 to 28.2% in 2014. It could be shown that authorisation procedures with single integrated protocols take significantly longer until initial authorisation (58 vs. 53 days) requires more substantial amendments (1.9 vs. 1.2 amendments per CTA) and the approval of the entirety of amendments takes longer to process as compared to standard protocols (22 vs. 14 days). Nevertheless, applicants prefer the use of integrated protocols due to higher time and cost economy for the entire phase I development process. CONCLUSION: Although clinical trials (CTs) following integrated protocols are partly more time-consuming and costly, still, time and/or money may be saved during drug development due to the fact that overall, fewer CTs are needed than with standard protocols. Hence, the main reason for the increasing use of integrated protocols is improved time and cost efficiencies when conducting CTs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00228-017-2335-y) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-09-18 2017 /pmc/articles/PMC5684304/ /pubmed/28921395 http://dx.doi.org/10.1007/s00228-017-2335-y Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Clinical Trial
Fruhner, Kevin
Hartmann, Gunther
Sudhop, Thomas
Analysis of integrated clinical trial protocols in early phases of medicinal product development
title Analysis of integrated clinical trial protocols in early phases of medicinal product development
title_full Analysis of integrated clinical trial protocols in early phases of medicinal product development
title_fullStr Analysis of integrated clinical trial protocols in early phases of medicinal product development
title_full_unstemmed Analysis of integrated clinical trial protocols in early phases of medicinal product development
title_short Analysis of integrated clinical trial protocols in early phases of medicinal product development
title_sort analysis of integrated clinical trial protocols in early phases of medicinal product development
topic Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684304/
https://www.ncbi.nlm.nih.gov/pubmed/28921395
http://dx.doi.org/10.1007/s00228-017-2335-y
work_keys_str_mv AT fruhnerkevin analysisofintegratedclinicaltrialprotocolsinearlyphasesofmedicinalproductdevelopment
AT hartmanngunther analysisofintegratedclinicaltrialprotocolsinearlyphasesofmedicinalproductdevelopment
AT sudhopthomas analysisofintegratedclinicaltrialprotocolsinearlyphasesofmedicinalproductdevelopment